Compare CINT & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | KMDA |
|---|---|---|
| Founded | 1995 | 1990 |
| Country | Brazil | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 460.3M |
| IPO Year | 2021 | 2013 |
| Metric | CINT | KMDA |
|---|---|---|
| Price | $3.17 | $7.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $5.62 | ★ $13.50 |
| AVG Volume (30 Days) | 66.4K | ★ 71.8K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 5.43% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.62 | $9.50 |
| Revenue Next Year | $9.65 | $12.63 |
| P/E Ratio | ★ $17.94 | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.80 | $6.55 |
| 52 Week High | $6.06 | $9.35 |
| Indicator | CINT | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.82 | 44.44 |
| Support Level | $3.10 | $7.66 |
| Resistance Level | $3.62 | $8.58 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 66.14 | 40.25 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.